Increased risk of salivary gland cancer among women with a previous cancer diagnosis

Objective Many head and neck cancers (HNCs) have genomic features seen in breast malignancy. We sought to analyze the risk of second primary HNC following an index breast cancer. Study Design Retrospective cohort study. Setting National database from the SEER registry (Surveillance, Epidemiology, and End Results). Subjects and Methods Within the SEER database, 223,423 women diagnosed with index breast cancer from 1992 to 2002 were identified. We calculated standard incidence ratios (SIRs) for all head and neck sites with 10-year follow-up. Results Women diagnosed with an index breast cancer did not exhibit higher likelihood of developing second primary HNC (SIR = 0.99; 95% CI, 0.90-1.07). The risk was determined for each subsite of the head and neck, and salivary gland cancer presented the highest risk. Patients with index breast cancer were 83% more likely to develop salivary gland cancer than what would be expected in the general population (SIR = 1.83; 95% CI, 1.49-2.22). An overall trend of increased risk was observed for salivary gland cancers between 1992 and 2002. There was no significant higher risk observed for the other head and neck subsites. Conclusion Patients with index breast cancer did not have a higher-than-expected risk of developing HNC. We did find an increased incidence of salivary gland cancers among patients with index breast cancer. Patients were 80% more likely to develop salivary gland cancer than that expected within the population. These findings warrant further investigation on the relationship between salivary gland and breast malignancy.

Download Full-text

A randomised phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs Androgen Deprivation Therapy (ADT) in patients with recurrent and/or metastatic, Androgen Receptor (AR) expressing, Salivary Gland Cancer (SGC)

10.26226/morressier.596cd2b8d462b80292387c64 ◽

2017 ◽

Author(s):

Carmela Caballero

Keyword(s):

Salivary Gland ◽

Androgen Receptor ◽

Androgen Deprivation Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Androgen Deprivation ◽

Salivary Gland Cancer ◽

Efficacy And Safety

Download Full-text

Su1228 Increased Risk of Colorectal Cancer in Patients With Prior Ovarian Cancer Diagnosis: A Population Based US Study

Gastroenterology ◽

10.1016/s0016-5085(14)61474-8 ◽

2014 ◽

Vol 146 (5) ◽

pp. S-408

Author(s):

Yezaz A. Ghouri ◽

Sachin Batra ◽

Nirav C. Thosani ◽

Sushovan Guha

Keyword(s):

Colorectal Cancer ◽

Ovarian Cancer ◽

Cancer Diagnosis ◽

Population Based ◽

Increased Risk

Download Full-text

Systemic Therapy for Salivary Gland Cancer

Salivary Gland Pathology ◽

10.1002/9781119730248.ch14 ◽

2021 ◽

pp. 455-469

Author(s):

Janakiraman Subramanian ◽

Lara Kujtan

Keyword(s):

Salivary Gland ◽

Systemic Therapy ◽

Salivary Gland Cancer

Download Full-text

Anti-seizure medication is not associated with an increased risk to develop cancer in epilepsy patients

Journal of Neurology ◽

10.1007/s00415-020-10379-4 ◽

2021 ◽

Author(s):

Jenny Stritzelberger ◽

Johannes D. Lang ◽

Tamara M. Mueller ◽

Caroline Reindl ◽

Vivien Westermayer ◽

...

Keyword(s):

Cancer Risk ◽

Cancer Diagnosis ◽

Index Date ◽

Control Group ◽

Protective Effects ◽

Promoting Effect ◽

Increased Risk ◽

Comorbidity Index ◽

Preclinical And Clinical Studies ◽

Risk Of Cancer

Abstract Objective Whether anti-seizure medication (ASM) increases the risk for cancer has been debated for decades. While for some ASM, a carcinoma-promoting effect has been suspected, carcinoma-protective effects have been shown for other ASM. However, the issue remains unresolved as data from preclinical and clinical studies have been inconsistent and contradictory. Methods We collected anonymous patient data from practice neurologists throughout Germany between 2009 and 2018 using the IMS Disease Analyzer database (QuintilesIMS, Frankfurt, Germany). People with epilepsy (PWE) with an initial cancer diagnosis and antiepileptic therapy prior to the index date were 1:1 matched with a control group of PWE without cancer according to age, gender, index year, Charlson Comorbidity Index, and treating physician. For both groups, the risk to develop cancer under treatment with different ASMs was analyzed using three different models (ever use vs. never use (I), effect per one (II) and per five therapy years (III). Results A total of 3152 PWE were included (each group, n = 1,576; age = 67.3 ± 14.0 years). The risk to develop cancer was not significantly elevated for any ASM. Carbamazepine was associated with a decreased cancer risk (OR Model I: 0.699, p < .0001, OR Model II: 0.952, p = .4878, OR Model III: 0.758, p < .0004). Significance Our findings suggest that ASM use does not increase the risk of cancer in epilepsy patients.

Download Full-text

Prostate cancer diagnosis is associated with an increased risk of erectile dysfunction after prostate biopsy

Yearbook of Urology ◽

10.1016/j.yuro.2013.02.011 ◽

2013 ◽

Vol 2013 ◽

pp. 92-93

Author(s):

A.W. Shindel

Keyword(s):

Prostate Cancer ◽

Erectile Dysfunction ◽

Cancer Diagnosis ◽

Prostate Biopsy ◽

Prostate Cancer Diagnosis ◽

Increased Risk

Download Full-text

Exposure‐toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer

International Journal of Cancer ◽

10.1002/ijc.33797 ◽

2021 ◽

Author(s):

Stefanie D. Krens ◽

Wim Boxtel ◽

Maike J. M. Uijen ◽

Frank G. A. Jansman ◽

Ingrid M. E. Desar ◽

...

Keyword(s):

Salivary Gland ◽

Renal Cell Cancer ◽

Renal Cell ◽

Cell Cancer ◽

Salivary Gland Cancer ◽

Relationship Of ◽

Toxicity Relationship

Download Full-text

Receipt of Screening Mammography by Insured Women Diagnosed With Breast Cancer and Impact on Outcomes

Journal of the National Comprehensive Cancer Network ◽

10.6004/jnccn.2020.7801 ◽

2021 ◽

Author(s):

Marissa B. Lawson ◽

Christoph I. Lee ◽

Daniel S. Hippe ◽

Shasank Chennupati ◽

Catherine R. Fedorenko ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Diagnosis ◽

Late Stage ◽

Breast Cancer Diagnosis ◽

Screening Mammography ◽

Socioeconomic Deprivation ◽

Tumor Characteristics ◽

Stage Disease ◽

Increased Risk ◽

Late Stage Disease

Background: The purpose of this study was to determine factors associated with receipt of screening mammography by insured women before breast cancer diagnosis, and subsequent outcomes. Patients and Methods: Using claims data from commercial and federal payers linked to a regional SEER registry, we identified women diagnosed with breast cancer from 2007 to 2017 and determined receipt of screening mammography within 1 year before diagnosis. We obtained patient and tumor characteristics from the SEER registry and assigned each woman a socioeconomic deprivation score based on residential address. Multivariable logistic regression models were used to evaluate associations of patient and tumor characteristics with late-stage disease and nonreceipt of mammography. We used multivariable Cox proportional hazards models to identify predictors of subsequent mortality. Results: Among 7,047 women, 69% (n=4,853) received screening mammography before breast cancer diagnosis. Compared with women who received mammography, those with no mammography had a higher proportion of late-stage disease (34% vs 10%) and higher 5-year mortality (18% vs 6%). In multivariable modeling, late-stage disease was most associated with nonreceipt of mammography (odds ratio [OR], 4.35; 95% CI, 3.80–4.98). The Cox model indicated that nonreceipt of mammography predicted increased risk of mortality (hazard ratio [HR], 2.00; 95% CI, 1.64–2.43), independent of late-stage disease at diagnosis (HR, 5.00; 95% CI, 4.10–6.10), Charlson comorbidity index score ≥1 (HR, 2.75; 95% CI, 2.26–3.34), and negative estrogen receptor/progesterone receptor status (HR, 2.09; 95% CI, 1.67–2.61). Nonreceipt of mammography was associated with younger age (40–49 vs 50–59 years; OR, 1.69; 95% CI, 1.45–1.96) and increased socioeconomic deprivation (OR, 1.05 per decile increase; 95% CI, 1.03–1.07). Conclusions: In a cohort of insured women diagnosed with breast cancer, nonreceipt of screening mammography was significantly associated with late-stage disease and mortality, suggesting that interventions to further increase uptake of screening mammography may improve breast cancer outcomes.

Download Full-text

Impact of cancer on the risk of unplanned 30-day readmissions.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.6581 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. 6581-6581

Author(s):

Alexander Qian ◽

Edmund Qiao ◽

Vinit Nalawade ◽

Nikhil V. Kotha ◽

Rohith S. Voora ◽

...

Keyword(s):

Cancer Patients ◽

Cancer Diagnosis ◽

Hospital Admissions ◽

Reference Group ◽

Cancer Site ◽

Cancer Type ◽

Logistic Regression Models ◽

Increased Risk ◽

Initial Hospitalization ◽

The Impact

6581 Background: Hospital readmission are associated with unfavorable patient outcomes and increased costs to the healthcare system. Devising interventions to reduce risks of readmission requires understanding patients at highest risk. Cancer patients represent a unique population with distinct risk factors. The purpose of this study was to define the impact of a cancer diagnosis on the risks of unplanned 30-day readmissions. Methods: We identified non-procedural hospital admissions between January through November 2017 from the National Readmission Database (NRD). We included patients with and without a cancer diagnosis who were admitted for non-procedural causes. We evaluated the impact of cancer on the risk of 30-day unplanned readmissions using multivariable mixed-effects logistic regression models. Results: Out of 18,996,625 weighted admissions, 1,685,099 (8.9%) had record of a cancer diagnosis. A cancer diagnosis was associated with an increased risk of readmission compared to non-cancer patients (23.5% vs. 13.6%, p < 0.001). However, among readmissions, cancer patients were less likely to have a preventable readmission (6.5% vs. 12.1%, p < 0.001). When considering the 10 most common causes of initial hospitalization, cancer was associated with an increased risk of readmission for each of these 10 causes (OR range 1.1-2.7, all p < 0.05) compared to non-cancer patients admitted for the same causes. Compared to patients aged 45-64, a younger age was associated with increased risk for cancer patients (OR 1.29, 95%CI [1.24-1.34]) but decreased risk for non-cancer patients (OR 0.65, 95%CI [0.64-0.66]). Among cancer patients, cancer site was the most robust individual predictor for readmission with liver (OR 1.47, 95%CI [1.39-1.55]), pancreas (OR 1.36, 95%CI [1.29-1.44]), and non-Hodgkin’s lymphoma (OR 1.35, 95%CI [1.29-1.42]) having the highest risk compared to the reference group of prostate cancer patients. Conclusions: Cancer patients have a higher risk of 30-day readmission, with increased risks among younger cancer patients, and with individual risks varying by cancer type. Future risk stratification approaches should consider cancer patients as an independent group with unique risks of readmission.

Download Full-text